302799-84-4Relevant academic research and scientific papers
Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4- benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[ 11C]one, as a potent NR1A/2B subtype selective NMDA PET radiotracer
Roger, Gaelle,Lagnel, Beatrice,Besret, Laurent,Bramoulle, Yann,Coulon, Christine,Ottaviani, Michelle,Kassiou, Michael,Bottlaender, Michel,Valette, Heric,Dolle, Frederic
, p. 5401 - 5408 (2007/10/03)
Recently, a new series of potent and highly subtype-selective 1-(heteroarylalkynyl)-4-benzylpiperidine antagonists of the NMDA receptors has been described by Pfizer Laboratories. In this series, 5-[3-(4-benzylpiperidin- 1-yl)prop-1-ynyl]-1,3-dihydrobenzo
Subtype-selective N-methyl-D-aspartate receptor antagonists: Synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines
Wright,Gregory,Kesten,Boxer,Serpa,Meltzer,Wise,Espitia,Konkoy,Whittemore,Woodward
, p. 3408 - 3419 (2007/10/03)
4-[4-(4-Benzylpiperidin-1-yl)but-1-ynyl]phenol (8) and 4-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-phenol (9) are potent NR1A/2B receptor antagonists (IC50 values 0.17 and 0.10 μM, respectively). Administered intraperitoneally, they both potentia
